 Passive immunization with polyclinal hyperimmunoglobulin, HIG, therapy provides immediate protection against a range of pathogens by transferring immunoglobulins to patients, but the protection is passive and requires an effective dose to be maintained until a natural adaptive immune response is mounted or the pathogen agent is cleared. The current review discusses key considerations for different pathogens and suggests improvements during on learnings from development of HIGs in response to public health threats such as Zika, influenza and severe acute respiratory syndrome coronavirus 2. This article was authored by Tharmila Tharmalingam, Xiaobing Han, Ashley Wozniak and others.